2012
UK Renal Association, Gateshead, UK
‘Endotoxin and other Microbial Derived Substances and Aseptic Peritonitis’
2007
PD Initiatives, Dutch Nephrologists program, Berlin, Germany
‘Glucotoxicity in Peritoneal Dialysis – Solutions to the Solution!’
‘Workshop: New PD solutions and technics’
2005
Nephrology Physicians, LLC. South Bend, IN
‘PD today and Tomorrow”
2005
Canadian Nephrologists Forum, Health Science Center, St. Johns, Newfoundland, Canada
Advanced PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Canadian Nephrologists Forum, Atlantic Health Science Centre, St. John, New Brunswick, Canada
‘Advanced PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Canadian Nephrologists Forum, Dr. G.Dumont Hospital, Moncton, New Brunswick, Canada
‘Advanced PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Baxter 23r d Home Dialysis Conference, Sydney, Australia‘2005 Peritoneal Dialysis Update’
2005
Canadian Nephrologists Forum, Vancouver, Canada
‘Advanced PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Canadian Nephrologists Forum, Foothills Hospital, Calgary, Canada
‘Advanced PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Nephrology Physicians, LLC. South Bend, IN
‘PD today and Tomorrow”
2005
Canadian Nephrologists Forum, Health Science Center, St. Johns, Newfoundland, Canada
Advanced PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Canadian Nephrologists Forum, Edmonton, Canada
‘Advanced PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Portuguese ISPD NA visiting Nephrologists, Deerfield, IL
‘Advanced PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Italian ISPD NA visiting Nephrologists, Deerfield, IL
‘Advanced PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Canadian Nephrologists Forum, Toronto, Canada
‘New PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Canadian Nephrologists Forum, Hamilton, Ontario, Canada
‘New PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2005
Canadian Nephrologists Forum, Etobicoke, Ontario, Canada
‘New PD Solutions: Demonstrated Clinical Benefits and Emerging Evidence’
2004
Global Biocompatibility: From Membrane to Patient, Copenhagen, Denmark
‘Exploring local aspects of global biocompatibility’
2004
Options in Renal Replacement, Flemish MDs, Dublin, Ireland
‘Clinical benefits of new PD solutions’
2004
Canadian Nephrologists Forum, San Antonio
‘Baxter Renal R&D – a Perspective for 2004’
2003
Nordic Kidney Days, Hveragerdi, Iceland
‘Baxter Senior Lecture’
2003
Baxter PD Forum, Tokyo, Japan
‘Product R&D and Emerging Technologies’
2003
Diseñando el futuro, juntos, Jerez, Spain
‘Baxter R&D and Emerging Technologies’
2002
ISPD Asia, Hong Kong
‘Peritoneal membrane viability – the role of solution biocompatibility’
2002
Disegnare il futuro…insieme, Genoa, Italy
‘Organ Replacement Technologies: Xenotransplantation, stem cell biology, tissue engineering’
2002
Canadian Nephrologists Physioneal™ pre-launch meeting, Tampa, Florida
‘Pre-clinical and clinical performance of Physioneal’
2001
Canadian Consultants meeting, Whistler, Canada
‘Future R&D in Baxter’
‘Biocompatibility of PD solutions’
Initiatives – Dutch Nephrologists – Dublin, Ireland
‘PD solution biocompatibility – a portfolio approach’
2000
Commemorative Symposium “Baxter – 20 Years of CAPD in Brazil”, Florianopolis, Brazil
‘PD solution Biocompatibility’
‘The potential for a disconnect catheter system for peritoneal dialysis’
2000
Physioneal™ Technical Marketing Plan – Oslo, Norway
‘Biological and clinical indices of biocompatibility with bicarbonate/lactate PD solutions’
2000
Physioneal™ Technical Marketing Plan – Bergen, Norway
‘Biological and clinical indices of biocompatibility with bicarbonate/lactate PD solutions’
2000
Physioneal™ Technical Marketing Plan – Helsinki, Finland
‘Biological and clinical indices of biocompatibility with bicarbonate/lactate PD solutions’
1999
French Nephrologists Pre-ASN Meeting, Deerfield, IL
‘Biological and clinical indices of biocompatibility with bicarbonate/lactate PD solutions’
1999
Bicarbonate/Lactate Investigators Meeting – Florence, Italy
‘Ex vivo and in vitro biocompatibility of Bicarbonate/Lactate’
1999
Physioneal™ Technical Marketing Plan – Odense, Denmark
Over 70 nephrologists and dialysis nurses, representing 90% of Danish customer base
1999
Physioneal™ Technical Marketing Plan – Uppsala, Sweden
0ver 40 nephrologists and nurses from Uppsala and Stockholm area
1999
Physioneal™ Technical Marketing Plan – Karolinska Hospital, Stockholm, Sweden
10-15 nephrologists and nurses from Karolinska and nearby Dandryd Hospital
1999
Physioneal™ Technical Marketing Plan – Göteborg, Sweden
Dr. Kersten Nättorp, Nu-Sjukvården NAL, Medicinkliniken, Trollhätten
Dr. Ulf Strömbom, Medicinkliniken, Varberg
Dr. Ann-Cathrine Johansson, Univ Sjh Sahlgrenska, Njurmedicin Divisionen, Göteborg
1999
Physioneal™ Technical Marketing Plan – Turku, Finland
Drs. Kaj Metsarinne and Marrku Asola – Turku University Hospital
1999
Physioneal™ Technical Marketing Plan – Helsinki, Finland
Drs. Carola Grönhagen-Riska, Agneta Ekstrand and Eero Honkanen – Helsinki University Hospital
1999
Physioneal™ Technical Marketing Plan – Tampere, Finland
Professor Amos Pasternack, Asst Professor Jukka Mustonen, Drs. Ilpo Ala-Houhala, Ole Wirta and Heikki Saha – Tampere University Hospital
1998
Baxter Australian Consultants meeting, Norfolk Island
‘Biocompatibility of Bicarbonate-lactate PD solutions’
‘New developments in percutaneous access’
1998
Physioneal™ Technical Marketing Plan – Uppsala, Sweden
Drs. Ulla Backman and Björn Wikström – Uppsala Akademiska University Hospital
Dieter Hultström – Gävle County Hospital
1998
Singapore Nephrology Customer Visits
Professor Eval Lee – National University Hospital
Dr. Abeed Pall – Singapore General Hospital
Ms. Ann Flett, Julie Millward – National Kidney Foundation
1997
American Society of Nephrology Annual Meeting: HD expert’s booth session
‘Biocompatibility of modified cellulosic membranes’
1997
Baxter Biocompatibility Consultants Group, Madrid, Spain
‘PD solution biocompatibility: the scientific rationale of bicarbonate-lactate as the buffer’ and
‘A portfolio of solutions for PD: biocompatibility perspectives’
1997
Physioneal™ Technical Marketing Plan – France
Dr. B. Morel, Centre Hospitalier, Chambery
Dr. S. Lavaud & Professor Chanaud, CHRU, Reims
Professor Mourad, Hopital Lapeyronie, Montpellier
1997
Novacor Division; 1997 Clinical Investigator’s meeting, San Francisco, CA
‘Infection Management’
1997
Physioneal™ Technical Marketing Plan – Italy and the U.K.
Professor A. De Vecchi, Osp. Maggiore Policlinico, Milan, Italy
Professor G. La Greca and M. Feriani, Osp. Reg. S. Bortolo, Vicenza, Italy
Professor G. Canepa, Osp. Reg. S. Martino, Genoa, Italy
Dr. Jonathan Kwan, St. Helier Hospital, Carshalton, Surrey, U.K.
Dr. Paul Altman, Oxford, U.K.
1997
Baxter Biocompatibility Consultants Group, Florence, Italy
‘PD solution biocompatibility: the scientific rationale of bicarbonate-lactate as the buffer’ and
‘A portfolio of solutions for PD: biocompatibility perspectives’
1996
Gruppo di studio della dialisi peritoneale della societa’italiana di nefrologia
PD perspectives in the year 2000: Baxter Research, Stressa, Italy
‘Biocompatibility of PD solutions: the role of bicarbonate-lactate combinations’
1996
Dutch Nephrologists Meeting, McGaw Park, IL
‘Biocompatibility of PD solutions: the role of bicarbonate-lactate combinations’
1996
EDTA Satellite Symposium: Bio-adequacy in dialysis, Amsterdam
‘Biocompatibility and fluid quality in dialysis’
1995
German Nephrologists ASN Satellite Meeting, San Diego.
‘Peritoneal host defense mechanisms’ and ‘PD solution biocompatibility’
1995
National Taiwan University Hospital, Taipei, Taiwan.
‘Catheter associated infection’ and ‘Peritoneal dialysis solution biocompatibility’
1995
Chang Gung Memorial Hospital, Taipei, Taiwan.
‘Catheter associated infection’ and ‘Peritoneal dialysis solution biocompatibility’
1995
Veterans General Hospital, Taipei, Taiwan.
‘Catheter associated infection’ and ‘Peritoneal dialysis solution biocompatibility’
1995
Baxter PD Forum, Tokyo, Japan
i} ‘Important Factors in PD solution biocompatibility’
ii} ‘Results of the Mupirocin clinical trial’
iii} ‘Advances in new PD catheter development’
1995
Iwate University Hospital, Morioka, Japan
‘Long-term viability of the peritoneal membrane’ and ‘PD solution biocompatibility’
1995
Saitama Medical College
I} ‘Long-term viability of the peritoneal membrane’
II} ‘PD solution biocompatibility’
1994
Baxter European Nephrology Consultants Annual Meeting, Sevilla, Spain
i} ‘Solution Biocompatibility: issues and controversies’
ii} ‘Results of the Mupirocin clinical trial’
1994
Baxter U.S. Nephrology Consultants Annual Meeting, Laguna Niguel, CA
‘The CAPD mupirocin clinical trial: preliminary results’
1994
Baxter Canadian Nephrologists Consultants Annual Meeting, Bermuda
i} ‘Results of the Mupirocin clinical trial’
ii} ‘Cellulosics and synthetics – a discreet or confounding description’
1993
Baxter European Hemodialysis Advisory Council, Vitznau, Switzerland
i} ‘Sterile dialysate in hemodialysis: definition and requirements’
ii} ‘Biocompatibility beyond complement activation’
1993
Baxter European Nephrologists Consultants Annual Meeting, Chicago, IL
‘Percutaneous Access – Future trends’
1993
Baxter U.S. Nephrologist Consultants Annual Meeting, Scottsdale, AZ
‘Peritoneal Dialysis Access Problems and Solutions – Future Trends’
1992
Baxter Canadian Nephrologists Annual Meeting, Turnberry Isle, FL
‘Therapy update: exit site infections’
1991
Baxter Dialysis Physicians Percutaneous Access mtg, Turnberry Isle, FL
‘Percutaneous access in CAPD: future prospects’
1990
Baxter Japanese Nephrologists Meeting, Miyazake, Japan
‘New initiatives in CAPD access’
1990
Baxter Canadian Nephrologists Annual Meeting, Acapulco, Mexico
i} ‘Backfiltration in high flux dialysis’
ii} ‘Update in CAPD catheter-associated biofilm’
1989
Baxter Japanese Nephrologists Meeting, Tokyo, Japan
‘The immunobiology of the dialyzed peritoneum’
1989
Baxter Renal Division Medical Advisory Board, Deerfield, IL
‘CAPD associated-infection: causes and interventions’
1988
Issues in Contemporary Hemodialysis: Baxter Symposium, Monte Carlo
‘The potential for and experimental measurement of microbial pyrogen transport in high flux hemodialysis membranes’
1988
Baxter U.S. Nephrologists Consultants Annual Meeting, Laguna Niguel, CA
‘The role of host defense in CAPD associated peritonitis: Perspectives’
1987
Baxter U.S. Nephrologist Consultants Annual Meeting, Naples, FL
‘New developments in percutaneous access systems for peritoneal dialysis’
1986
Travenol U.S. Nephrologist Consultants Annual Meeting, Scottsdale, AZ
‘Biofilm and foreign body infection in CAPD’
1983
Travenol Symposium: ‘A new era in dialysis’, Columbus, OH
‘Microbiological considerations in peritoneal dialysis’
1983
Travenol Symposium: ‘A new era in dialysis’, Los Angeles, CA
‘Microbiological considerations in peritoneal dialysis’
1983
Travenol Symposium: ‘A new era in dialysis’, San Francisco, CA
‘Microbiological considerations in peritoneal dialysis’
1979
Hospital Pharmacists Forum, Manchester Royal Infirmary, England
‘Freeze-thawing of frozen antibiotic solutions’
HankinsonHolmes 